News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39%. Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on ...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEBSep 24, 2024 · Japan is the second major market where Kisunla has received approval. Kisunla was first approved in the United States in July 2024. INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults ...
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early...
Results from Lilly’s Landmark Phase 3 Trial of Donanemab …
WEBJul 17, 2023 · Donanemab specifically targets deposited amyloid plaque and has been shown to lead to plaque clearance in treated patients. Treatment with donanemab significantly reduced amyloid plaque levels regardless of baseline pathological stage of …
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Eli Lilly's donanemab, an Alzheimer's drug, gets FDA endorsement
WEBJun 10, 2024 · An FDA advisory panel endorsed the experimental Alzheimer's drug donanemab that studies showed slowed early stages of the fatal mind-robbing disease.
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab …
WEBJul 17, 2023 · An FDA approval of Eli Lilly’s donanemab would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer’s, the fifth-leading cause of death for adults...
FDA approves donanemab, Eli Lilly’s treatment for early ... - CNN
WEBJul 2, 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.